Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

4,090 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical course of 2019 novel coronavirus disease (COVID-19) in individuals present during the outbreak on the Diamond Princess cruise ship.
Kato H, Shimizu H, Shibue Y, Hosoda T, Iwabuchi K, Nagamine K, Saito H, Sawada R, Oishi T, Tsukiji J, Fujita H, Furuya R, Masuda M, Akasaka O, Ikeda Y, Sakamoto M, Sakai K, Uchiyama M, Watanabe H, Yamaguchi N, Higa R, Sasaki A, Tanaka K, Toyoda Y, Hamanaka S, Miyazawa N, Shimizu A, Fukase F, Iwai S, Komase Y, Kawasaki T, Nagata I, Nakayama Y, Takei T, Kimura K, Kunisaki R, Kudo M, Takeuchi I, Nakajima H. Kato H, et al. Among authors: fujita h. J Infect Chemother. 2020 Aug;26(8):865-869. doi: 10.1016/j.jiac.2020.05.005. Epub 2020 May 13. J Infect Chemother. 2020. PMID: 32405245 Free PMC article.
PNPO-PLP axis senses prolonged hypoxia in macrophages by regulating lysosomal activity.
Sekine H, Takeda H, Takeda N, Kishino A, Anzawa H, Isagawa T, Ohta N, Murakami S, Iwaki H, Kato N, Kimura S, Liu Z, Kato K, Katsuoka F, Yamamoto M, Miura F, Ito T, Takahashi M, Izumi Y, Fujita H, Yamagata H, Bamba T, Akaike T, Suzuki N, Kinoshita K, Motohashi H. Sekine H, et al. Among authors: fujita h. Nat Metab. 2024 May 31. doi: 10.1038/s42255-024-01053-4. Online ahead of print. Nat Metab. 2024. PMID: 38822028
Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials.
Kimball AB, Jemec GBE, Sayed CJ, Kirby JS, Prens E, Ingram JR, Garg A, Gottlieb AB, Szepietowski JC, Bechara FG, Giamarellos-Bourboulis EJ, Fujita H, Rolleri R, Joshi P, Dokhe P, Muller E, Peterson L, Madden C, Bari M, Zouboulis CC. Kimball AB, et al. Among authors: fujita h. Lancet. 2024 May 22:S0140-6736(24)00101-6. doi: 10.1016/S0140-6736(24)00101-6. Online ahead of print. Lancet. 2024. PMID: 38795716
4,090 results